Lu177 PRRT For Neuroendocrine Tumors (Nets)

 Nuclear Medicine, as a treatment protocol for Neuroendocrine Tumors (NETs) has been used in many countries across the globe for many a years.

PRRT or Peptide Receptor Radionuclide Therapy is a type of Nuclear Medicine Therapy in which a cell-targeting protein or peptide is combined with a small amount of radioactive material that created a special type of radiopharmaceutical known as a Radiopeptide. This radiopeptide is injected into a Neuroendocrine Tumor patient’s bloodstream.

Unlike healthy cells, the neuroendocrine tumor cells or NET cells have proteins on their cell surface. These proteins, also known as receptors, bind themselves to hormones, such as somatostatin. Peptide Receptor Radionuclide Therapy or PRRT with lutetium 177 dotatate or Lu177 targets these receptors with radiopeptides and deliver a high dose of radiation to the tumor cells.

How PRRT for NET works? – Method of Action

1.        A peptide i.e. a group of amino acids is created that can bind to the receptors on the tumor cell’s surface.

2.      This peptide is then paired with a radioactive atom using a chelator (a bonding agent).

3.      This combination of the peptide and the radioactive material creates a radiopeptide.

4.      This radiopeptide is injected into a Neurodendocrine Tumor (NET) patient’s bloodstream.

5.      The radiopeptide finds the NET cancer cell’s somatostatin receptors and binds itself to them.

6.      The radiopeptide emits radiation that kills the NET cancer cell.

Read More at Lu177 PRRT For Neuroendocrine Tumors (Nets)

Comments

Post a Comment

Popular posts from this blog

where is use Yttrium-90 and Its Side Effect

  Yttrium-90 or Y-90 is a commonly used isotope in the medical field specially in departments like nuclear medicine and radiation oncology for radiation therapy. This radioisotope is relied upon to provide a prescribed amount of radiation to a targeted area , such as a tumor. One of the most common uses of Y90 is during an internal radiation therapy called radioembolization. Radioembolization or  Transarterial Radioembolization  using Y-90 involves the use of glass/ resin spheres that are filled with the isotope and placed directly into the blood supply of the liver tumor through a minimally invasive procedure. These spheres get lodged within the tumor itself. The doctors then block off the blood vessels to prevent blood flow (embolization). These Y-90 labelled spheres then get to work by radiating and destroying the tumor. Commonly, Y-90 labelled spheres are used for the treatment of liver tumors, primary hepatocellular carcinoma (HCC) and unresectable primary colore...
Read more

Tare Vs Tace For Hepatocellular Carcinoma and Net Patients

  The incidence of Hepatocellular Carcinoma or HCC has been increasing over the past several years and several studies have projected that the incidence of HCC will continue to rise in the coming years. Transarterial Chemoembolisation or TACE has been the initial treatment modality for HCC and has a huge body of evidence from several studies and clinical trials. Therefore, for long TACE has been a preferred treatment algorithm for unresectable HCC. However, as the experience of  Transarterial Radioembolisation or TARE  has evolved, it is playing an increasingly important role in the treatment of unrespectable HCC. Studies and trials have shown that TARE has many potential advantages over TACE and there is now substantial evidence to favor TARE over TACE. The many potential advantages of TARE when compared with TACE are as below: · Several studies have shown a statistically significant overall survival advantage with TARE as compared to TACE. · TARE has better health-relat...
Read more

Is PRRT Right For You?

Image
  How do doctors determine that PRRT should be the treatment of choice for a neuroendocrine tumour? PRRT  or Peptide Receptor Radionuclide Therapy is a molecular therapy that is one of the accepted modes of treatment for Neuroendocrine Tumours (NETs). Before we go on to discuss the above topic at hand, let me explain PRRT. In PRRT, a radiopeptide is created by combining a small amount of radioactive material or radionuclide (Yttrium-90 or Y-90 and Lutetium-177 or Lu-77) with a cell-targeting protein. This radiopeptide, when injected into a neuroendocrine tumour patient’s bloodstream, travels and binds itself to the neuroendocrine tumour cells to deliver a high dose of radiation that targets only the cancer cells. Also Read:  How Does a Typical PRRT Day look like? Doctors recommend PRRT for patients diagnosed with Advanced Metastatic or Progressive Neuroendocrine Tumours (NETs); also for NET patients who are ineligible for surgery; and also for those NET patients w...
Read more